The role of sex steroids in bone growth and development: Evolving new concepts

Endocrinologist

Volumn 6, Issue 5, 1996, Pages 362-368

  Bachrach, Bert E ^a   Smith, Eric P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; FOLLITROPIN; GONADORELIN DERIVATIVE; GROWTH HORMONE; LUTEINIZING HORMONE; MUTANT PROTEIN; PARATHYROID HORMONE; SEX HORMONE; SOMATOMEDIN C; TESTOSTERONE; THYROID HORMONE; VITAMIN D;

ADULT; BONE DENSITY; BONE DEVELOPMENT; BONE GROWTH; BONE MASS; BONE MATURATION; BONE MINERALIZATION; CASE REPORT; DRUG MECHANISM; ENZYME DEFICIENCY; FEMALE; GENE MUTATION; HORMONE RESISTANCE; HUMAN; MALE; PRECOCIOUS PUBERTY; PSEUDOHERMAPHRODITISM; REVIEW; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0029795174     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-199609000-00003     Document Type: Review

References (69)

1. Korach KS: Insights from the study of animals lacking functional estrogen receptor. Science 1994; 266: 1524-28.
2. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS: Androgen receptor defects: historical, clinical and molecular perspectives. Endocrine Rev 1995; 16: 271-95.
3. Caruso-Nicoletti M, Cassorla FG, Skerda MC, Ross JL, Loriaux DL, Cutler GB Jr: Short-term, low-dose estradiol accelerates ulnar growth in boys. J Clin Endocrinol Metab 1985; 61: 896-98.
4. Cutler GB, Cassorla FG, Ross JL, et al.: Pubertal growth: physiology and pathophysiology. Rec Prog Hormone Res 1986; 42: 443-70.
5. Orwoll ES, Klein RF: Osteoporosis in men. Endocrine Rev 1995; 16: 87-116.
6. Mora S, Weber G, Guaneri MP, Nizzoli G, Pasolini D, Chiumello G: Effect of estrogen replacement therapy on bone mineral content in girls with Turner syndrome. Obstet Gynecol 1992; 79: 747-51.
7. Finkelstein JS, Klibanski KA, Neer RM, et al.: Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69: 776-83.
8. Carrascosa A, Audi L, Ferrandez MA, Ballabriga A: Biological effects of androgens and identification of specific dihydrotestosterone-binding sites in cultured human fetal epiphyseal chondrocytes. J Clin Endocrinol Metab 1990; 70: 134-40.
9. Smith EP, Boyd J, Frank GR, et al.: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056-61.
10. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER: A syndrome of female pseudohermaphroditism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (p450). J Clin Endocrinol Metab 1994; 78: 1287-92.
11. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689-98.
12. Laue L, Kenigsberg D, Pescovitz OH, et al.: Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989; 320: 496-502.
13. Laue L, Jones J, Barnes KM, Cutler GB: Treatment of familial male precocious puberty with spironolactone, testolactone and deslorelin. J Clin Endocrinol Metab 1993; 76: 151-5.
14. Ritzen EM: Pubertal growth in genetic disorders of sex hormone action and secretion. Acta Paediatr Suppl 1992; 383: 22-5.
15. Zachmann M, Prader A, Sobel EH, et al.: Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls. J Pediatr 1986; 108: 694-7.
16. Preece MA, Pan H, Ratcliffe SG: Auxological aspects of male and female puberty. Acta Paediatr Suppl 1992; 383: 11-3.
17. Lubahn DB, Moyer JS, Golding TS, Couse JF, Smithies O: Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993; 90: 11162-6.
18. Bachrach BE, Beck AM, Li XJ, et al.: Bone histomorphometric analysis of a 29-year-old man with estrogen resistance caused by a estrogen receptor gene mutation: severe osteopenia and evidence for decreased osteoblastic and osteoclastic activity (abstract). Program and Abstracts of The Endocrine Society, 77th Annual Meeting, June 14-17, 1995, p. 444.
19. Simpson ER, Mahendroo MS, Means GD, et al.: Aromatase cytochrome p450, the enzyme responsible for estrogen biosynthesis. Endocrine Rev 1994; 15: 342-55.
20. George FW, Wilson JD: Sex determination and differentiation. In The Physiology of Reproduction, edited by Knobil E, Neil JD, pp. 3-28, New York, Raven Press 1994.
21. Pescovitz OH: The endocrinology of the pubertal growth spurt. Acta Paediatr Suppl 1990; 367: 119-25.
22. Hermanussen M, Geiger-Binoit K, Burmeister J: Differential effects of oestrogen treatment on the proportionality of growth in tall girls. Eur J Pediatr 1989; 149: 14-7.
23. Uriarte MM, Baron J, Garcia HB, Barnes KM, Loriaux DL, Cutler GB Jr: The effect of pubertal delay on adult height in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1992; 74: 436-40.
24. Caldwell PD, Smith DW: The XXY (Klinefelter's) syndrome in childhood: detection and treatment. J Pediatr 1972; 80: 250-8.
25. Tanner JM, Whitehouse RH, Hughes PC, Carter BS: Relative importance of growth hormone and sex steroid for the growth at puberty of trunk length, limb length, and muscle width in growth hormone deficient children. J Pediatr 1976; 89: 1000-8.
26. Kletter GB, Kelch RP: Clinical review 60: effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab 1994; 79: 331-334.
27. Paul D, Conte FA, Grumbach MM, Kaplan SL: Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at median age of less than 5 years. J Clin Endocrinol Metab 1995; 80: 546-51.
28. Horton WA: The biology of bone growth. Growth Genet Horm 1990; 6: 1-5.
29. Bettman HK, Goldman HS, Abramowicz M, Sobel EH: Oxandrolone treatment of short stature: effect on predicted mature height. J Pediatr 1971; 79: 1018-23.
30. Baron J, Klein KO, Yanovski JA, Novosad JA, et al.: Induction of growth plate cartilage ossification by basic fibroblast growth factor. Endocrinology 1994; 135: 2790-3.
31. Muenke M, Schell U: Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 1995; 11: 308-13.
32. Inzucchi SE, Robbins RJ: Clinical review 61: effects of growth hormone on human bone biology. J Clin Endocrinol Metab 1994; 79: 691-94.
33. Rogol AD: Anabolic steroid therapies for growth disorders. Hosp Pract (Ofice Edition) 1989; 24: 89-92.
34. Joss EE, Schmidt HA, Zuppinger KA.: Oxandrolone in constitutional delayed growth, a longitudinal study up to final height. J Clin Endocrinol Metab 1988; 69: 1109-15.
35. Keenan BS, Richards GE, Ponder SW, Dallas JS, Nagamani M, Smith ER: Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 1993; 76: 996-1101.
36. Chernausek SD: Turner syndrome: effect of estrogen on growth. Proceedings of the 8th Annual Investigators Meeting, National Cooperative Growth Study, October 27-30, 1994; 18: 9.
37. Rogol AD: Growth and growth hormone secretion at puberty: the role of gonadal steroid hormones. Acta Paediatr Suppl 1992; 383: 15-20.
38. Metzger DL, Kerrigan JR: Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male precocious puberty. J Clin Endocrinol Metab 1994; 79: 513-8.
39. Silver JJ, Einhorn TA: Osteoporosis and aging. Current update. Clin Orthopaed 1995; 316: 10-20.
40. Gambert SR, Schultz BM, Hamdy RC: Osteoporosis: clinical features, prevention and treatment. Endocrinol Metab Clin North Am 1995; 24: 317-71.
41. Bachrach LK: Bone mineralization in childhood and adolescence. Curr Opin Pediatr 1993; 5: 467-73.
42. Turner RT, Riggs BL, Spelsberg TC: Skeletal effects of estrogen. Endocrine Rev 1994; 15: 275-300.
43. Duursma SA, Raymakers JA, Boereboom FTJ, Scheven BAA: Estrogen and bone metabolism. Obst Gynecol Surv 1991; 47: 38-44.
44. Devogelaer JP, De Cooman S, Nagant de Deuxchaisnes C: Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. Maturitas 1992; 15: 17-23.
45. Theintz G, Buchs B, Rizzoli R, et al.: Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75: 1060-5.
46. Slemenda CW, Reister TK, Hui SL, Miller JZ, Christian JC, Johnston CC Jr: Influences on skeletal mineralization in children and adolescents: evidence for varying effects of sexual maturation and physical activity. J Pediatr 1994; 125: 201-7.
47. Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A: Osteopenia in men with a history of delayed puberty. N Engl J Med 1992; 326: 600-4.
48. Rubin K, Schirduan V, Gendreau P, Sarfarazi M, Mendola R, Dalsky G: Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty. J Pediatr 1993; 123: 863-70.
49. Bachrach LK, Katzman DK, Litt IF, Guido D, Marcus R: Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 1991; 72: 602-6.
50. Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC: The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995; 80: 898-904.
51. Sylven L, Hagenfeldt K, Ringertz H: Bone mineral density in middle-aged women with Turner's syndrome. Eur J Endocrinol 1995; 132: 47-52.
52. Horowitz M, Wishart JM, O'Loughlin PD, Morris HA, Need AG, Nordin BE: Osteoporosis and Klinefelter's syndrome. Clin Endocrinol 1992; 36: 113-8.
53. Scane AC, Francis RM: Risk factors for osteoporosis in men. Clin Endocrinol 1993; 38: 15-6.
54. MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK: Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979; 49: 905-16.
55. Need AG, Horowitz M, Walker CJ, CHatterton BE, Chapman IC, Nordin BE: Cross-over study of fat-corrected forearm mineral content during nandrolone deconaoate therapy for osteoporosis. Bone 1989; 10: 3-6.
56. Vanderschueren D, Van Herck E, Sulker AM, et al.: Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J Bone Miner Res 1993; 8: 801-9.
57. Soule SG, Conway G, Prelevic GM, Prentice M, Ginsburg J, Jacobs HS: Osteopenia as a feature of the androgen insensitivity syndrome. Clin Endocrinol 1995; 43: 6671-5.
58. Parfitt AM. The two faces of growth: benefits and risks to bone integrity. Osteopor Int 1994; 4: 382-98.
59. Orwoll ES, Biliziotes M: Heterogeneity in osteoporosis: men versus women. Rheumat Dis Clin North Am 1994; 20: 671-89.
60. Parfitt AM, Mathews CH, Villanueva AR, Kleerekoper M, Frame B, Rao DS: Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis: implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 1983; 72: 1396-409.
61. Delichatsios HK, Lane JM, Rivilin RS: Bone histomorphometry in men with spinal osteoporosis. Calcif Tissue Int 1995; 56: 359-63.
62. Eriksen EF, Mosekilde L, Melsen F: Trabecular bone resorption depth decreases with age: differences between normal males and females. Bone 1985; 6: 141-6.
63. Federman DD: Life without estrogen. N Engl J Med 1994; 331: 1088-9.
64. Frank GR: The role of estrogen in pubertal skeletal physiology: epiphyseal maturation and mineralization of the skeleton. Acta Paediatr 1995; 84: 627-30.
65. Raisz LG, Wiita B, Artis A, et al.: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996; 81: 37-43.
66. Bernecke PM, Willvonseder R, Resch H: Decreased estrogen levels in male patients with primary osteoporosis. J Bone Miner Res 1995; 10(suppl 1):S445.
67. Bardin CW, Swerdloff RS, Santen RJ: Androgens: risks and benefits. J Clin Endocrinol Metab 1991; 73: 4-7.
68. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr: Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 1994; 94: 2475-80.
69. Wilson JD. A new beginning for estrogen physiology. J Clin Invest 1994; 94: 2176.